Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$22.00 - $117.33
Next Earnings Date
May 07 2025
Next Earnings Date
May 07 2025
Latest price
Market Cap | $7.31B |
EV | $6.71B |
Shares Outstanding | 123.69M |
Beta | 0.15 |
Analyst Rating | BUY |
Analyst Target Price | $143.25 |
P/E 2025E | 40.87x |
P/Revenue 2025E | 8.07x |
Revenue | 22.60% |
EPS | 11.40% |
Operating Cash Flow | 5.70% |
Free Cash Flow | 5.40% |
Revenue | 35.90% |
EPS | 70.50% |
Operating Cash Flow | 35.70% |
Free Cash Flow | 47.70% |
Gross Margin 2025E | 98.47% |
Net Profit Margin 2025E | 20.91% |
ROE 2025E | 46.80% |
ROCE 2024 | 23.56% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Corcept Therapeutics Incorporated
CORT
Sector
Healthcare
Industry
Biotechnology
CEO
Belanoff, Joseph
Employees
500
Website
www.corcept.comIPO Date
2004-04-14
Headquarters
149 Commonwealth Drive, Menlo Park, California, 94025, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved